Lots of uncertainty with the planned separation
Pros
The people and compensation and benefits were great, but lack of confidence with new senior leadership, many of the best employees and talent have jumped ship during the transition due to loss of pension, ans serious concern of the viability of the business model without the bigger resources of pharma and medical device business units.
Cons
Senior leadership is untested, lots of talented leaders and individuL contributors have left during the transition, risky to be Ina business that could be stopped up by private equity, due to prepping for IPO, many non stratwgic decisions were made that were short term focused and not in the best long term interest of the new separated company, mission and values that were not aligned to the doctors, nurses, patients, etc.
